100 likes | 234 Views
THE LEUKEMIA & LYMPHOMA SOCIETY PRESENTATION AT CDC-HEMATOLOGIC CANCER ANNUAL MEETING MAY 16, 2008 ATLANTA, GEORGIA. OUR MISSION. Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families”. PATIENT SERVICES.
E N D
THE LEUKEMIA & LYMPHOMA SOCIETY PRESENTATION AT CDC-HEMATOLOGIC CANCER ANNUAL MEETING MAY 16, 2008 ATLANTA, GEORGIA
OUR MISSION • Cure leukemia, lymphoma, Hodgkin’s disease • and myeloma, and improve the quality of life of patients and their families”
PATIENT SERVICES • Family Support Group (9,500 participants) • The Trish Greene Back to School • Patient Financial Aid (16,958 recipients ) • First Connection/Ambassador ( 7,400 matches) • Chapter education programs (reached 46,000 patients and caregivers) • National Teleconferences and Web casts (447,166 participants) • Co-Pay Program (over $2 million since January 2008)
GOAL 1: • 1. Address the disparities in patient access to cancer clinical trials • Cancer Clinical Trials and the Underserved: Community Based Strategies
GOAL 2 • 2. Address the cultural gaps for Hispanic Patients and other underserved patients in removing barriers to cancer care • Pilot developed with Chapters in 7 sites: • Houston • Atlanta • New York City • Chicago • Miami • San Diego • Orange County
Goal 2 continued • Chapters received intensive cultural competency training and support from the Intercultural Cancer Council. • Collaboration meetings with Community Based Groups were held in each pilot community. • Community support in the form of programs and services planned with CBO’s.
Goal 2 continued • Cancer Fact Sheet on Blood Cancers Among Minorities and the Underserved Developed. • Training and participation at the 11th Biennial Symposium on Minorities, the Medically Underserved and Cancer.
Goal 3 • 3. Provide proactive patient navigation for blood cancer patients • --Information Resource Center proactively navigates patients with need of immediate and on-going support. • --Provides crisis intervention, referral to clinical trials and long term strategies for living with blood cancers.